World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Number of total visits: 33481211

Number of visits today: 7856

Number of downloads: 16667456

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Suwabe T, Barrera FJ, Rodriguez-Gutierrez R, Ubara Y, Hogan MC. Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials. PLoS One 2021;16:e0257606. [PMID: 34559824 DOI: 10.1371/journal.pone.0257606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]

For:

Suwabe T, Barrera FJ, Rodriguez-Gutierrez R, Ubara Y, Hogan MC. Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials. PLoS One 2021;16:e0257606. [PMID: 34559824 DOI: 10.1371/journal.pone.0257606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]

Number	Citing Articles
1	Bakaj I, Pocai A. Metabolism-based approaches for autosomal dominant polycystic kidney disease. Front Mol Biosci 2023;10:1126055. [PMID: 36876046 DOI: 10.3389/fmolb.2023.1126055] [Reference Citation Analysis]
2	Duijzer R, Barten TRM, Staring CB, Drenth JPH, Gevers TJG. Treatment of Polycystic Liver Disease: Impact on Patient-reported Symptom Severity and Health-related Quality of Life. J Clin Gastroenterol 2022;56:731-9. [PMID: 35997709 DOI: 10.1097/MCG.0000000000001749] [Reference Citation Analysis]
3	European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of cystic liver diseases. J Hepatol 2022;77:1083-108. [PMID: 35728731 DOI: 10.1016/j.jhep.2022.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4	Norcia LF, Watanabe EM, Hamamoto Filho PT, Hasimoto CN, Pelafsky L, de Oliveira WK, Sassaki LY. . HMER 2022;Volume 14:135-61. [DOI: 10.2147/hmer.s377530] [Reference Citation Analysis]
5	Yoo JJ, Jo HI, Jung EA, Lee JS, Kim SG, Kim YS, Kim BK. Evidence of nonsurgical treatment for polycystic liver disease. Ther Adv Chronic Dis 2022;13:20406223221112563. [PMID: 35898920 DOI: 10.1177/20406223221112563] [Reference Citation Analysis]
6	Bais T, Gansevoort RT, Meijer E. Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease. Drugs. [DOI: 10.1007/s40265-022-01745-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]